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Abstract
Objective—To examine the course of depression during the treatment of depressed adolescents
who had recently attempted suicide.
Method—Adolescents (N=124), age 12–18 years, with a 90-day history of suicide attempt, a
current diagnosis of depressive disorder (96.0% had major depressive disorder), and a Children's
Depression Rating Scale-Revised (CDRS-R) score of 36 or greater, entered a 6-month treatment
with antidepressant medication, cognitive-behavioral therapy focused on suicide prevention, or
their combination (Comb), at five academic sites. Treatment assignment could be either random or
chosen by study participants. Intent-to-treat, mixed effects regression models of depression and
other relevant ratings were estimated. Improvement and remission rates were computed with the
last observation carried forward.
Results—Most patients (N=104 or 84%) chose treatment assignment and, overall, three-fourths
(N=93) received Comb. In Comb, CDRS-R declined from a baseline adjusted mean of 49.6 (SD
12.3) to 38.3 (8.0) at week 12, and to 27.0 (10.1) at week 24 (p<0.0001), with a Clinical Global
Impression-defined improvement rate of 58.0% at week 12, and 72.2% at week 24; and a
remission (CDRS-R ≤28) rate of 32.5% at week 12 and 50.0% at week 24. CDRS-R and the Scale
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for Suicidal Ideation (SSI) scores were correlated at baseline (r=0.43, p<0.0001), and declined in
parallel.
Conclusions—When vigorously treated with a combination of medication and psychotherapy,
depressed adolescents who have recently attempted suicide show rates of improvement and
remission of depression that appear comparable to those observed in non-suicidal depressed
adolescents.
Keywords
adolescents; suicide; depression; treatment
Suicidal ideation and behavior are among the possible manifestations of depression, and the
risk for suicide is intrinsic in the depressive psychopathology.1,2 When depression is
associated with prominent suicidal symptoms, such as a recent suicide attempt, the
underlying psychopathology may be more complex and the treatment response different,
with respect to both efficacy and safety, than observed in depression without significant
suicidal symptoms.
The efficacy of selective serotonin reuptake inhibitors (SSRI), cognitive-behavioral therapy
(CBT), and their combination for the treatment of adolescent depression is well documented.
3–7 The evidence, however, is in large part derived from randomized controlled clinical
trials that excluded or restricted the participation of youths who recently attempted suicide.
Most depression treatment studies have excluded patients deemed at high risk for suicide
due to ethical and practical reasons as these patients are considered to be in need of more
comprehensive treatment and intensive monitoring than usually provided under a research
protocol. Consequently, clinicians have been left with incomplete information about the
therapeutic benefits of interventions for depressed suicidal adolescents. This gap is
especially problematic since depression is a major but malleable risk factor for suicide, and
its treatment constitutes the main approach to suicide prevention.8
The Treatment of Adolescent Suicide Attempters Study (TASA) was an uncontrolled, pilot
investigation to assess the feasibility of systematically treating adolescents who were
clinically depressed and had recently attempted suicide.9 Participants in TASA received a
thorough evaluation at study entry and were then treated with antidepressant medication
and/or manualized CBT, which was developed specifically to address the suicidal risk with
the aim of preventing recurrence of suicidal behavior (Cognitive Behavioral Therapy for
Suicide Prevention; CBT-SP).10 The primary analyses showed that 12% of the patients
experienced another suicide attempt during the 24weeks of TASA.9
In this paper, we report on the change in the ratings of depressive symptoms, global scores
of illness severity, and level of functioning observed over the 24 weeks of treatment in
TASA. The purpose of these analyses is to describe trends in depressive symptom change
and to estimate, within the limitations imposed by the non-experimental, uncontrolled nature
of the study, whether treatment response appears to be consistent with that reported in non-
suicidal depressed adolescents.
Method
Sample and Design
TASA was a multi-site study to evaluate the feasibility of identifying, enrolling, and treating
a sample of depressed adolescents with a recent history of suicide attempt.9 Treatment
consisted of antidepressant medication and cognitive-behavioral therapy with focus on
suicide prevention (CBT-SP). Females and males youths, aged 12–18 years, were eligible
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for participation if they had made a suicide attempt in the last 90 days, met current criteria
for major depressive disorder, dysthymic disorder, or depressive disorder not otherwise
specified, on the Schedule for Affective Disorders and Schizophrenia for School-Age
Children-Present and Lifetime Version,11 and had a score of 36 or greater on the Children's
Depression Rating Scale- Revised (CDRS-R).12 Exclusion criteria included substance
dependence, bipolar disorder, psychosis, and pervasive developmental disorders. Patients
were enrolled at five academic sites (University of Texas-Southwestern Medical Center,
Dallas, TX; Western Psychiatric Institute and Clinic,Pittsburgh, PA; Johns Hopkins
University, Baltimore, MD; Duke University Medical Center, Durham, NC; and New York
State Psychiatric Institute-Columbia University/New York University, New York, NY),
between December 2003 and June 2006.
The study started as a randomized trial, but, after about nine months of low enrollment
despite intensive recruitment efforts, the design was changed so that patients and their
families could either accept randomization or choose which treatment to receive. The study
was reviewed and approved by the local institutional review boards, and monitored by an
independent data and safety monitoring board.
Treatment
The treatment lasted 6 months and consisted of manualized CBT-SP, antidepressant
pharmacotherapy (Med), following an adaptation of the Texas Medication Algorithm for
adolescent depression,13 or a combination of these two modalities (Comb). A detailed
description of CBT-SP is separately provided.10 In brief, CBT-SP was specifically aimed at
modifying known risk factors for suicide, such as depression, with the goal of preventing
recurrence of suicidal behavior.10 CBT-SP consisted of up to 22 sessions, including both
individual and parent-youth sessions, and incorporated five key elements: 1) chain analysis
of the index suicide attempt; 2) safety planning to reduce current suicide risk; 3) case
conceptualization (i.e., formulation of the patient's specific cognitive, behavioral, affective,
and contextual problems); 4) skill acquisition and enhancement (e.g., behavioral activation,
cognitive restructuring, and problem-solving); and 5) relapse prevention. Med followed an
established treatment algorithm for pharmacological treatment of depression in youths,
which started with a comprehensive evaluation for possible use of antidepressant and
included, as a first step, monotherapy with a selective serotonin reuptake inhibitor (SSRI),
followed, in case of non response, by a different SSRI as step 2, and an alternate class
(venlafaxine, duloxetine, mirtazapine, or bupropion) as step 3, with the option of
augmenting with lithium or other antidepressant in case of partial response. 13
Trained psychotherapists provided the CBT-SP under the supervision of senior experts, and
across site weekly telephone conferences were held to review cases and discuss treatment
strategies. Psychopharmacologists provided the medication treatment, and weekly telephone
conferences were held to review cases and ensure consistency across sites.
Assessments
The primary outcome of TASA was recurrence of a suicide event. Suicidal events included
suicide attempts, interrupted suicide attempts, as well as high levels of suicidal ideation that
necessitated emergency evaluation or hospitalization. As separately reported, a suicide event
occurred in 19.5% of the participants, with 12.0% making a suicide attempt (9). The present
report focuses on depressive symptoms and other related outcomes.
The primary measure of depressive symptoms was the total score on the CDRS-R, which is
a clinician-rated 17-item scale based on direct interviewing of patient and parent. The
CDRS-R was administered by independent evaluators, who were experienced clinicians with
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a master degree education or higher. Independent evaluators were trained to ensure
acceptable inter-rater reliability and remained blind to patient treatment assignment. Ratings
were obtained at study entry and at 6, 12, 18, and 24 weeks afterwards.
In addition, the Montgomery-Asberg Depression Rating Scale (MADRS)14 was
administered by the pharmacotherapists at each visit. The MADRS is a 10-item clinician
rating scale that was originally developed for use in adults, but has been applied to the
assessment of depression symptoms in children.15 Patients completed the Beck Depression
Inventory16 and the Beck Scale for Suicidal Ideation (SSI)17 at baseline and weeks 6, 12,
18, and 24. Anxiety symptoms were measured on the Multidimensional Anxiety Scale for
Children (MASC),a self-rated, 39-item questionnaire.18
Overall severity of psychopathology and improvement were rated on the Clinical Global
Impression Severity (CGI-S) and Improvement (CGI-I) scales,19 and level of functioning on
the Child Global Assessment Scale (CGAS)20 by the independent evaluator at baseline and
weeks 6, 12, 18, and 24. At the same time points, the patient completed the Social
Adjustment Scale (SAS).21
Data Analysis
Data management and quality control were centralized at KAI-Research, Inc., under an
NIMH contract. The data were analyzed with intent-to treat approach. For the continuous
dependent variables, mixed effects regression models were estimated in which the intercepts
and the slopes for change in the outcome over the course of the study were allowed to vary
randomly across individuals. Gender, race (white vs. non-white), comorbidity (presence of
mental disorder other than depression), pre-treatment history of additional suicide attempts,
time from most recent suicide attempt at entry into TASA, and impairment severity (CGI-S
> 4) were assessed as potential time-invariant predictors of this variation and of end-of-
treatment improvement (i.e., final CGI-1 below 3) or remission status (i.e., final CDRS-R
below 29). Site was controlled as a fixed effect in the model.
Although regression curves on the CDRS-R were computed for each treatment group,
variation in treatment effect across group is difficult to interpret because group assignment
occurred largely through self-selection and the large majority of subjects ended up in the
combined treatment group (Comb). For this reason, more detailed analyses of the outcome
measures were conducted for Comb alone.
Results
Baseline
A total of 124 adolescents, age 12–18 (mean 15.7 ± SD 1.5), 77.4% females, 79.8% White,
participated in the study (Table 1). The large majority (96.0%) met diagnostic criteria for
major depressive disorder (10.5% had both major depressive disorder and dysthymic
disorder). Most (N=104 or 83.9%) chose their treatment rather than being randomized, and
93 (75.0%) received Comb. Comb patients had more severe depression (mean CDRS-
R=52.1 ± SD 12.0) than Med patients (43.4 ± 11.1, t=2.58, p=0.01) or CBT patients (46.9 ±
14.7, t=2.56, p=0.01). There was also a higher prevalence of comorbid anxiety and more
functional impairment in Comb than in the other two treatment groups.
Premature discontinuation
Overall, 39 patients (31%) dropped out prior of the end of the 24-week study (22 patients or
18% in the first 12 weeks). In the Comb group, 14 patients dropped out by week 12 (15%)
and 27 (29%) by week 24. The reasons for discontinuation were: suicidal intent with
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inability to commit to safety plan (N=2), lack of adherence to treatment (N=5), need for
different treatments and services (N=9), and withdrawal of consent or failure to return for
visits for unspecified reasons (N=23). One patient, a 16-year old boy, died of suicide 20
days after he completed the 24-week study; he had chosen and received combined treatment,
and had shown improvement in TASA, reaching remission from the depressive disorder by
week 8. Prior to entering TASA, this patient had attempted suicide three times using
methods such as gunshot attempt, hanging, and carbon monoxide poisoning.
Change during Treatment
In all three treatment groups there was a significant decline in depressive symptoms as
measured by the CDRS-R (Fig.1). The slope of the CDRS-R decline was not influenced by
gender (gender*time p=0.70), race (White vs. non-White*time p=0.31, or history of multiple
suicide attempts (attempt*time p=0.76).
In Comb, based on intent-to-treat mixed effect regression models, CDRS-R declined from a
baseline adjusted mean of 49.6 ± SD 12.3 to 38.3 ± 8.0 at week 12, and to 27.0 ± 10.1 at
week 24 (p<0.0001). The mean change from baseline was 14.6±15.1 at week 12, and
18.1±16.7 at week 24. The improvement rate, based on a CGI-I of 1 or 2, was 58.0% at
week 12, and 72.2% at week 24. The remission rate, defined by a CDRS-R ≤28, was 32.5%
at week 12, and 50.0% at week 24 (Table 2). The C-GAS scores improved from 49.3± 10.4
at baseline to 61.0±8.0 at week 12, and to 72.6 ± 11.4 at week 24. The SAS scores improved
from 58.0±15.1 at baseline to 48.6±16.6 at week 12 and to 39.8±12.3 at week 24.
Still in Comb, statistically significant changes from baseline were detected on the other
measures. The CGI-S declined from an adjusted mean of 4.3± SD 1.0 at entry to 3.2 ± 0.8 at
week 12 and 2.0 ± 1.0 at week 24; the BDI from 21.9 ±13.5 at entry to 13.8±9.0 at week 12
and 5.7 ±9.3 at week 24; and the MADRS from 22.9±10.5 at entry to 13.8±6.9 at week 12
and 4.7±7.7 at week 24. The patient-rated MASC declined from 46.0±18.1 at entry to
40.0±14.9 at week 12 and 33.6±16.4 at week 24, while the parent-rated MASC went from
49.1±15.4 at entry to 44.9±12.0 at week 12, and 40.6±12.5 at week 24.
No predictors of improvement and remission status at week 24 were identified among the
examined baseline variables, which included patient's gender, race, comorbidity, history of
more than one suicide attempt, time from most recent suicide attempt, severity of illness,
and study site.
The CDRS-R and the Scale for Suicidal Ideation (SSI) scores were correlated at baseline
(r=0.43, p<0.001), and both declined significantly during treatment (time effect p<0.001).
When the CDRS-R was entered as a covariate in the SSI regression, the time effect of SSI
became non significant. Of the 23 suicidal events that occurred in TASA (involving a total
of 15 patients), 35% occurred during the first 4 weeks, and 83% during the first 12 weeks.
Discussion
In this study, depressed adolescents who had recently attempted suicide were systematically
diagnosed and treated in a 6-month feasibility study. As the study allowed for self-selection
of treatment by the participants, no causal inferences are possible. The three treatment
groups were diverse as to size, severity of depression and level of dysfunction, as more
severe patients preferred combined treatment over monotherapy (Table 1). However, the
data offer an opportunity to examine the changes in depressive symptoms and related
indexes of psychopathology and functioning that occurred over a period of 6 months during
which patients were intensively treated and closely monitored.
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The large majority of the participants received the combination of psychotherapy (CBT-SP)
and SSRI antidepressant medication (Comb). Thus, the results mainly apply to this treatment
group. In Comb, the rate of improvement (58% at week 12 and 72% at week 24) was
consistent with that observed in non-suicidal depressed adolescents treated with a
combination of CBT and SSRI medication in recently completed randomized clinical trials
(Table 2). The CDRS-R at study entry was, on average, lower in TASA than in the
randomized trials, probably reflecting the entry criteria used for this study. While caution
must be exercised when comparing results between studies, especially between randomized
trials and non-experimental studies, the remission rate in TASA was 32% at week 12 and
50% at week 24, which is comparable to that in the Treatment for Adolescents with
Depression Study (TADS), which was 37% at week 12 and 56% at week 24.23,24
With regard to the feasibility of including and treating depressed youths at high risk for
suicide in a treatment study, the retention rate in TASA at week 12 (85%) compares
favorably to that of other treatment studies in adolescent depression, although it declined to
71% by week 24 (Table 2). One must consider, however, that treatment was mainly chosen
by the participants in TASA, but randomly assigned in TADS and the other adolescent
clinical trials. A greater attrition rate might be expected in randomized trials involving
suicidal patients. As premature treatment discontinuation is a major obstacle to providing
care to suicidal adolescents, future studies will need to develop effective strategies for
patient retention.
The finding of a robust improvement in depressive symptomatology in TASA is consistent
with the results of a smaller study of psychotherapy in adolescents with repeated self-harm.
This study found that, by the end of the 7-month treatment, the depressive symptom scores
had declined by about 50% over the baseline.25 The results are also consistent with the data
from the Sequenced Treatment Alternatives to Relieve Depression study (STAR*D) in
adults, where history of having attempted suicide did not affect the rate of remission.26
The decrease in depressive symptoms was accompanied by a decrease in suicidal ideation as
indicated by the parallel decline of CDRS-R and SSI scores. The incidence of suicide
attempts during the 6-month period of TASA, however, was higher than observed in studies
of depressed adolescents who had not attempted suicide (Table 2). It should be noted that at
least one-third of the attempts occurred in the first 4 weeks of treatment and the large
majority (83%) in the first 12 weeks. This distribution of suicide attempts suggest that the
risk of reattempt is highest in the first three months of treatment, when depressive
symptoms, though improving, are still prominent, and then declines as depression abates.
The suicide that occurred about 3 weeks after completing TASA points at treatment
transition as another period of high risk. The fact that this patient had improved and reached
remission from depression while in treatment confirms that other factors, beside depression,
contribute to suicidal behavior.
A number of important limitations must be taken into account when interpreting these data.
First, as already underscored, the lack of randomization and experimental control prevents
drawing causal inferences about treatment effects, which cannot be disentangled from time
effects. Because of self-selection of treatment by the large majority of the TASA
participants, we cannot determine how CBT-SP, Med, and Comb compared with each other
with regards to efficacy or safety. Second, the CBT-SP administered in TASA is a particular
type of CBT that was modified to address the high suicidality risk, and, in this respect, was
different from the standard CBT developed for non-suicidal depressed adolescents. This
difference limits the comparisons with other clinical trials in depressed adolescents that used
standard CBT. Finally, patients with psychotic symptoms or prominent substance abuse
were excluded, thus limiting the generalizability of the findings. Given the prominence of
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substance abuse in increasing the risk for suicidal behavior, there is a need to identify
methods for including youths with substance abuse in future studies.
In conclusion, in this sample of depressed youths who had recently attempted suicide,
intensive treatment, mainly with a combination of CBT-SP and antidepressant medication,
was associated with rates of improvement and remission of depression that appear
comparable to those observed in non-suicidal depressed adolescents treated with combined
medication and CBT, thus supporting the broad relevance of clinical trials conducted in
depressed adolescents and the inclusion of this high risk population in future clinical trials.
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Figure 1. Child Depression Rating Scale-Revised Scores Over Timea
CBT: cognitive-behavioral therapy (N=17). Med: algorithmic SSRI medication treatment
(N=14). Comb: combination of CBT and Med (N=93).
aAdjusted means based on mixed effects regression models of the independent evaluator
ratings. Seventeen patients completed treatment after the end of the 6 months.
Mixed-model regression model: time: F=91.0, p<0.0001; treatment group differences at
baseline: F=4.3, p=0.001 (COMB>CBT, Med); treatment*time: F=0.93, p=0.40.
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Table 2
Depressive Symptoms Ratings during Combined CBT/Medication Treatment in TASA and Other Multisite
Studies in Adolescent Depression
Study TASA TADS5,6 ADAPT22 TORDIA7
Design patient choice randomized randomized randomized
Na 93b 107 105 166
Females 72% 56% 75% 70%
Age, yr, mean (SD) 15.7 (1.6) 14.6 (1.5) 14.0 (1.5) 16.0 (1.5)
Diagnosis Major depressive
(96% of the
sample)
Major depressive disorder Major depressive
disorder or 4
depressive
symptoms
Major depressive disorder
Suicidal history Suicide attempt in
the 90 days prior to
study entry
Youths at high-risk for
suicidality were excluded, but
29% of the participants had
significant suicidal ideation
About half of the
sample had
history of
suicidal behavior
58% of the participants had
clinically significant suicidal
ideation
Comorbidity 68% 52% 88% 52%
Drop-out by Week 12 15% 14% 11% 16%
Drop-out by Week 24a 29% 20% 17% -e
CDRS-Rc
 Baseline, mean (SD) 49.6 (12.3) 60.8 (6.2) 58.9 (10.5)e 59.2 (11.0)
 Week 12, mean (SD) 38.3 (8.0) 33.6 (8.6) 42.5 (16.8)e 36.9 (13.9)
 Week 24,e mean (SD) 27.0 (10.1) 30.0 (8.1) 36.4 (15.3)e -e
CGI-I-Response ratef
 Week 12 58.0% 71.0% 41.6% 59.0%
 Week 24e 72.2% 77.6% 53.1% -h
Remission rateg
 Week 12 32.5% 37% -h 31%
 Week 24e 50.0% 56% -h -h
C-GASc
 Baseline, mean (SD) 49.3 (10.4) 50.0 (7.5) 41.6 (6.0) 50.6 (7.7)
 Week 12, mean (SD) 61.0 (8.0) 66.6 (11.9) 52.1 (14.3) 65.1 (11.8)
 Week 24,e mean (SD) 72.6 (11.4) -h 57.2 (16.4) -h
Incidence of suicidal attemptsi
 By Week 12 12.9% 2.8% 6.9% 6.0%
 By Week 24e 15.1% 3.7% 7.1% -h
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Abbreviations: TASA: Treatment of Adolescent Suicide Attempters; TADS: Treatment for Adolescents with Depression Study; ADAPT:
Antidepressant and Psychotherapy Trial; TORDIA: Treatment of Resistant Depression in Adolescents; CDRS-R: Child Depression Rating Scale-
Revised; CGI-I: Clinical Global Impressions-Improvement; C-GAS: Children Global Assessment Scale
dActual scores. N=104 at baseline, N=100 at week 12 and N=98 at week 28.
a
Combined treatment group only
b
86 chose treatment and 7 were randomized
c
Adjusted means based on intent-to-treat regression analyses, except for ADAPT (see foot-note d)
e
Week 28 for ADAPT
f
Response: score of 1 (very much improved) or 2 (much improved) on the CGI-I, with last observation carried forward
g
Remission: CDRS-R ≤28, with last observation carried forward.
h
Data not available
i
Actual suicide attempt (i.e., excluding aborted or interrupted attempts)
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